---
title: ä¸Šæµ·å¾©æ˜Ÿç–«è‹— å…±ç­†
tags: COVID-19, ç–«è‹—, ä¸Šæµ·å¾©æ˜Ÿ, Pfizer-BioNTech, g0v
description: è’é›†æœ‰é—œPfizer-BioNTech COVID-19 Vaccineå’Œä¸Šæµ·å¾©æ˜Ÿ(Fosun)çš„è¨è«–
---
# Pfizer-BioNTechå’Œä¸Šæµ·å¾©æ˜Ÿç–«è‹— å…±ç­†
:::warning
å…±ç­†ç·¨å¯«ä½¿ç”¨èªªæ˜ï¼šé»é¸æ­¤é é¢å·¦ä¸Šæ–¹ã€Œç­† <i class="fa fa-pencil btn btn-default"></i>ã€çš„åœ–ç¤ºï¼Œå‘ˆç¾é»‘åº•ç•«é¢å¾Œå³å¯ç›´æ¥ç·¨å¯«ï¼Œç„¡é ˆå­˜æª”ï¼Œç³»çµ±æœƒè‡ªå‹•ä¿å­˜ã€‚å¯é€é[æ·»åŠ é€£çµçš„æ–¹å¼](https://hackmd.io/s/features-tw)ï¼Œå”åŠ©æŸ¥è­‰*å¾…æŸ¥è­‰çš„éƒ¨åˆ†*ã€‚
* æœ¬ç¯‡å…±ç­†é€£çµ Link of this noteï¼šhttps://hackmd.io/@planty/ryoz1tiKu
* [é˜²ç–«è³‡è¨Šç«™â”€å¯¦è­‰é†«å­¸æ•‘å°ç£](https://www.facebook.com/groups/2560340054261472/?multi_permalinks=2562464624049015) 
    :::spoiler ç¤¾åœ˜å®—æ—¨è©³ç´°è³‡è¨Šè«‹é»æˆ‘
        æœ¬ç¤¾åœ˜ä¸»è¦å®—æ—¨ç‚ºï¼šå‚³éæ­£ç¢ºçš„ç–«æƒ…æ¶ˆæ¯
        ç”±æ°‘çœ¾æå• - é†«å¸«è§£æƒ‘ - å°‡è³‡è¨Šå½™æ•´ã€‚
        ã€Œå¯¦è­‰é†«å­¸æ•‘å°ç£ã€ä¾†è‡ªå°ç£å„åœ°çš„ä½é™¢é†«å¸«çµ„æˆçš„åœ˜éšŠï¼Œåœ¨ç–«æƒ…æœŸé–“æŒçºŒç¿»è­¯åœ‹éš›é˜²ç–«ç›¸é—œæ–‡ç»ï¼Œå”åŠ©è§£ç­”ç–«æƒ…è¿·æ€ï¼Œå¹«åŠ©å°ç£æŒºéç–«æƒ…ã€‚
        ğŸ—£ æ°‘çœ¾æå•
        æ­¡è¿æ°‘çœ¾æå‡ºä»»ä½•é—œæ–¼ç–«æƒ…ç›¸é—œçš„ç–‘å•
        ğŸ‘©ğŸ»â€âš•ï¸é†«å¸«è§£æƒ‘
        æˆ‘å€‘å°‡é‚€è«‹æœ‰å°ˆæ¥­é†«ç™‚èƒŒæ™¯çš„é†«ç”Ÿè§£æƒ‘
        ğŸ“‘è³‡è¨Šå½™æ•´
        å½™æ•´ç¾æœ‰çš„ç–«æƒ…ç›¸é—œè³‡è¨Šï¼ŒæŒçºŒå‚³éæ­£ç¢ºæ¶ˆæ¯:::
:::

:::success
ç›®éŒ„
[TOC]
:::


## æ–¼cofacts[è¢«å›å ±çš„æ–‡ç« ](https://cofacts.tw/article/r58o53xp08zt)    
æ–¯æ–¯æœ‰2ç¨®ï¼Œæ‰€è¬‚çš„BNTç–«è‹—ä¹Ÿæœ‰2ç¨®å–”ï¼
BNTä¸€é–‹å§‹é€²å…¥è‡¨åºŠè©¦é©—çš„ç–«è‹—candidatesæœ‰BNT162b1å’ŒBNT162b2é€™å…©ç¨®ï¼Œä»¥ä¸‹ç°¡ç¨±b1ã€b2ï¼ŒBNTå’ŒPfizer(è¼ç‘)å®Œæˆä¸€äºŒæœŸè©¦é©—å¾ŒåŸºæ–¼å®‰å…¨æ€§å’ŒæŠ—é«”ç”¢ç”Ÿçš„æ•ˆæœ[æ±ºå®šæ”¾æ£„b1ã€åƒ…ä»¥b2ç¹¼çºŒå®Œæˆä¸‰æœŸè©¦é©—](https://www.nejm.org/doi/full/10.1056/NEJMoa2027906)ï¼Œè€Œä¸Šæµ·å¾©æ˜Ÿå’ŒBNTçš„åˆç´„ä½¿å…¶[å¾—ä»¥b1é€²è¡Œä¸­åœ‹å¢ƒå…§çš„è‡¨åºŠè©¦é©—](https://www.fosunpharma.com/uploads/20201110105645.PDF)ã€*ç™¼å±•è‡ªä¸»ç–«è‹—*ï¼Œé€™ä¹Ÿæ˜¯å»å¹´*ä¸‹åŠå¹´ä¸Šæµ·å¾©æ˜Ÿå°å¤–å®£ç¨±ä¸­åœ‹å·²ç¶“è‡ªä¸»ç™¼å±•å‡ºæ•ˆæœæ›´å‡ºè‰²çš„mRNAç–«è‹—*çš„èƒŒæ™¯ï¼Œåˆç´„åŒæ™‚ä¿éšœ*ä¸Šæµ·å¾©æ˜Ÿæ“æœ‰ä¸­åœ‹å€çš„BNTç–«è‹—ç¨å®¶ä»£ç†æ¬Š*ã€‚
ç”±æ–¼Pfizerå®Œå…¨ä¸­æ­¢äº†å°b1çš„ç ”ç™¼æŠ•å…¥ï¼Œ*ä¸Šæµ·å¾©æ˜Ÿçš„b1ä¸­åœ‹å€è‡¨åºŠè©¦é©—ä¹Ÿåœ¨äºŒæœŸå¡ä½ç„¡æ³•å®Œæˆ*ï¼Œ*æ–¼æ˜¯ä¸Šæµ·å¾©æ˜Ÿæ”¹ä»¥b2å‘ä¸­åœ‹æ”¿åºœç”³è«‹è—¥è­‰*ï¼Œä¸¦æ‰“ç®—å¾ªå…¶å®ƒè—¥å“çš„ç”³è«‹æ–¹å¼*å¼•ç”¨å…¨çƒè‡¨åºŠè©¦é©—çš„æ•¸æ“šç‚ºåƒè€ƒåŸºç¤*ï¼Œä½†æ˜¯ä¸Šæµ·å¾©æ˜Ÿå’ŒBNTçš„åˆç´„æ˜¯å»ºç«‹åœ¨ä»¥ä¸­åœ‹å€çš„è‡¨åºŠè©¦é©—æ•¸æ“šé€å¯©çš„å‰æä¸‹ï¼Œçªç„¶è¦æ”¹æˆå¼•ç”¨å…¨çƒè‡¨åºŠè©¦é©—æ•¸æ“šé€å¯©ï¼Œ*åˆå¾—ä»£ä½BNTå‘Pfizer æ”¯ä»˜ä¸€åŠçš„å…¨çƒè‡¨åºŠè©¦é©—æ•¸æ“šæˆæ¬Šé‡‘*ï¼Œå¯æƒ³è€ŒçŸ¥ï¼Œè¦è¦çŸ©çŸ©å¾å¾·åœ‹å¼•é€²çš„b2æˆæœ¬æ¯”èµ·b1äº‹å¯¦ä¸Šåˆå¤šäº†äº›é¡å¤–çš„æˆæ¬ŠåŠ æˆï¼Œç•¶ç„¶ï¼Œä¸Šæµ·å¾©æ˜Ÿå°b1çš„ç ”ç™¼æŠ•å…¥å’Œæ‰“é€šä¸­åœ‹å€å„ç¨®ç’°ç¯€çš„è¡ŒéŠ·å‰ç½®æˆæœ¬å¿…ç„¶å¾ˆå¯è§€ï¼Œä½†åé€¢ä¸­åœ‹æ”¿åºœç­–ç•¥æ€§ç™¼å±•åœ‹ç”¢ç–«è‹—ä¸¦åŠ ç¢¼ç–«è‹—å¤–äº¤ï¼Œä¸Šæµ·å¾©æ˜Ÿå¾å¾·åœ‹é€²å£çš„b2æ”¿æ²»ä¸æ­£ç¢ºã€çˆ¹ä¸ç–¼å¨˜ä¸æ„›ï¼Œè‡ªä¸»ç™¼å±•çš„b1åˆé¢è‡¨äºŒæœŸé‚„æœªå®Œæˆï¼Œå¯æƒ³è€ŒçŸ¥ä»–å€‘çš„å¿ƒæƒ…æˆ–è¨±åªæœ‰æ˜æœˆç…§æºæ¸ å·®å¯æ“¬â€¦â€¦
æ‰€ä»¥æˆ‘å€‘çš„CDCå’Œé™³æ™‚ä¸­éƒ¨é•·å¾ˆå²å®³ï¼Œä¸€é–‹å§‹å°±æƒ³ç›¡è¾¦æ³•è¦è·ŸPfizerç›´æ¥è«‡ï¼Œå› ç‚ºPfizeråªæœƒè³£b2å•Šï¼ä½†æ˜¯ä¸Šæµ·å¾©æ˜Ÿçš„ã€Œä¸­åœ‹å€ã€ç¨å®¶ä»£ç†æœ‰å…¶æ”¿æ²»ä¸Šçš„è§£é‡‹ç©ºé–“ï¼Œåªè¦å°ç£ä¸è¢«åœ‹éš›æ‰¿èªæ˜¯ç¨ç«‹åœ‹å®¶å°±å…ä¸äº†åœ¨é€™å€‹ç’°ç¯€ä¸Šé­é‡å£“åŠ›ï¼Œæ–¼æ˜¯éƒ¨é•·åˆèªªå¯ä»¥è«‹ä¸Šæµ·å¾©æ˜Ÿæˆ–æ˜¯æƒ³è¦ä»£ç†ä¸Šæµ·å¾©æ˜Ÿç”¢å“çš„ä»£ç†å•†æå‡ºè—¥è­‰ç”³è«‹ï¼Œå› ç‚ºæå‡ºç”³è«‹å°±å¿…é ˆèªªæ˜é€²ä¾†çš„æ˜¯b2é‚„æ˜¯b1ï¼Œå¤šéº¼ç›´æ¥äº†ç•¶çš„éæ¿¾æ–¹æ³•ï¼
[æ—ç¸£é•·è¦ç”¨å¯¶è²´çš„é ç®—æ›¿å—æŠ•ç¸£æ°‘æº–å‚™BNTç–«è‹—](https://tw.appledaily.com/politics/20210526/KKPHOLIDONBI3L3TH5VQIKUPNU/)ç•¶ç„¶ä»¤äººæ„Ÿå‹•ï¼Œä¸éBNTç–«è‹—æœ‰2ç¨®å–”ï¼Œä¸€å®šè¦æŒ‡åæ˜¯å¾·åœ‹é€²å£çš„b2ï¼Œæ¯åŠ‘æ¨™æº–å”®åƒ¹æ˜¯ç¾é‡‘20å…ƒï¼Œç¾åœ¨å¥‡è²¨å¯å±…ï¼Œæ‡‰è©²ä¸å¯èƒ½æ‹¿å¾—åˆ°æŠ˜æ‰£ï¼›å¦‚æœæ˜¯ä¸Šæµ·å¾©æ˜Ÿè‡ªä¸»ç™¼å±•ä½†æœªå®Œæˆçš„b1ï¼ŒåŸºæœ¬ä¸Šæ‡‰è©²æ˜¯è¦éŠ·æ¯€çš„æ±è¥¿ï¼Œè¡›ç¦éƒ¨ä¹Ÿä¸å¤§å¯èƒ½æœƒæ”¾è¡Œï¼Œå¦‚æœé‚„æ˜¯å¯ä»¥é€²ä¾†ã€ä¹Ÿé‚„æ˜¯æœ‰äººé¡˜æ„æ‰“ç•¶2æœŸè‡¨åºŠè©¦é©—å“ï¼Œè«‹å‹™å¿…ç°½å…è²¬è²æ˜ï¼Œç•¢ç«Ÿï¼Œæ–¯æ–¯æœ‰2ç¨®ï¼

é—œæ–¼BNTç–«è‹—æœ‰2ç¨®çš„å®Œæ•´æ•…äº‹å¯åƒè€ƒPfizerä¸»ç®¡çš„è²¼æ–‡åˆ†äº«å¦‚ä¸‹ï¼š`(å¼•ç”¨åœ¨ä¸‹æ–¹)`
https://www.facebook.com/1607652971/posts/10218529500261240/?d=n

## Carlos Linn è‡‰æ›¸è²¼æ–‡
[POæ–‡å…§å®¹ç‚ºå€‹äººæƒ³æ³•æˆ–è§€å¯Ÿ]:  
ä¸Šæµ·å¤æ˜Ÿæ“æœ‰BNTä¸­æ¸¯æ¾³ï¼Œ(è¢«å¼·æ‹‰é€²å»çš„å°ç£)çš„ç ”ç©¶é–‹ç™¼æ¬Šï¼Œå•†æ¥­æ¬Šï¼Œä½†æ˜¯ç›®å‰ä¸­åœ‹ç ”ç™¼çš„è‡¨åºŠè©¦é©—(investigational product BNT162b1)ï¼Œç¬¬äºŒæœŸæ²’æœ‰å®Œæˆå°±æ”¾æ£„äº†ï¼Œ[å¤æ˜Ÿä¸€ã€äºŒæœŸæ‰€åšçš„vaccine candidate æ˜¯BNT162b1](https://www.nature.com/articles/s41591-021-01330-9)ï¼Œ(b1å–”) ï¼Œ ä½†æ˜¯Pfizer and BioNTechåœ¨é€²å…¥Phase 2/3æ™‚å› ç‚ºBNT162b1çš„[worse safety profiles and less immunogenicity](https://www.nejm.org/doi/full/10.1056/NEJMoa2027906)ï¼Œæ”¾æ£„BNT162b1ï¼Œåœ¨Phase3åªé¸æ“‡BNT162b2ï¼Œè‡³æ–¼BNT162b1å·²ç¶“å®Œå…¨ä¸å†æŠ•å…¥ç ”ç™¼ã€‚ä¸Šæµ·å¤æ˜Ÿåœ¨2020åä¸€æœˆä¹Ÿåªèƒ½åœæ­¢BNT162b1ç ”ç™¼(Phase 2åœæ­¢ï¼Œå¥½ç©çš„æ˜¯ä¹æœˆPhase 1æ™‚é‚„ä¸æ–·å®£ç¨±ä¸­åœ‹äººç¨ç«‹è‡ªä¸»ç ”ç™¼BNT162b1å’Œè¼ç‘çš„ä¸ä¸€æ¨£ï¼Œæ˜¯æ›´ã€Œç²¾æº–ã€çš„antigen)ã€‚
11æœˆä¹‹å¾Œå¤æ˜Ÿç‚ºäº†åœ¨ä¸­åœ‹æŸ¥é©—ç™»è¨˜éœ€æ±‚ï¼Œåœ¨11æœˆåˆ°12æœˆé€²è¡ŒBNT162b2 ç¬¬äºŒæœŸæ©‹æ¥è©¦é©—(bridging study, 960åå—è©¦è€…)ï¼Œä¸éé™¤äº†Bridging studyå¤–ï¼Œä¸å†é€²è¡Œç‚ºäº†BNT162b2çš„ä¸­åœ‹BLAï¼Œåœ¨é«˜ç››è¡Œç‡çš„å…¶ä»–åœ°å€åœ‹å®¶åšç¬¬ä¸‰æœŸè‡¨åºŠè©¦é©—ã€‚ä¼¼ä¹å¤æ˜Ÿå’ŒBNTä¸å†åˆä½œæˆ–è€ƒæ…®ä¸­åœ‹çš„ç¨ç«‹è‡ªä¸»é–‹ç™¼è¨ˆç•«ï¼Œå°‡æ¯”ç…§å¤–å•†å…¬å¸å¼•ç”¨æ—¢æœ‰çš„global data ä¾†ç”³è«‹çš„ä½œæ³•ã€‚å¯¦éš›ä¸Šå°±è½‰è®Šç‚ºã€Œä»£ç†å•†ã€æŠ•è³‡äººã€è‚¡æ±ã€çš„ä½éšï¼Œ(é‚„å¥½æ˜¯Tier 1æ“æœ‰exclusively commercial rightçš„ã€Œç¨å®¶ã€ä»£ç†å•†)ã€‚é›…å„è‡£æ˜¯é¦™æ¸¯Tier 2ä»£ç†, å°ç£æ±æ´‹åŸä¾†ä¹Ÿæ˜¯æƒ³è¦ç•¶åœ¨å°ç£çš„Tier 2 ä»£ç†å•†å§ï¼Ÿ ä¸éã€Œä»£ç†å•†ã€å’Œã€Œæ®å®¢ã€æ‡‰è©²ä¸ä¸€æ¨£å§ï¼Ÿèƒ½å¤ BLAé€ä»¶è€…æ˜¯ä»£ç†å•†(æœ‰è—¥å•†åŸ·ç…§)ï¼Œä½†æ˜¯æ®å®¢(å¥½å¥‡ç‚ºä»€éº¼å°èªå«ç‰½ğŸ’)ä¸èƒ½é€ä»¶ï¼Œä¸éå¦‚æœè‡ªå·±ä¸€æ¯›éŒ¢éƒ½ä¸å‡ºï¼Œå…¨éƒ¨è¦æ”¿åºœçµ¦ï¼Œé€™è¡Œç‚ºåˆå¥½åƒæ˜¯æ®å®¢è¡Œç‚º? æ‰€ä»¥å¥½å¥‡[ã€Œé‡‘é–€ç¸£ã€å¦‚ä½•é€²å£å¤æ˜ŸBNTç–«è‹—](https://tw.appledaily.com/politics/20210518/7JJWYTYY5VGBZEKNIKCG4UFD74/)ï¼ŸBLA submission ç´°ç¯€å¤šå¦‚ç‰›æ¯›è€¶(æ‰€ä»¥æ˜¯æ®å®¢?)ï¼(å°äº†å°ç£è—¥äº‹è¦ç¯„é™åˆ¶åš´æ ¼ï¼Œè—¥å“æˆ–ç–«è‹—ä¸å¯ä»¥æœ‰æ°´è²¨æˆ–å¹³è¡Œè¼¸å…¥ï¼Œæ°´è²¨ä¸ç®¡æ˜¯ä¸æ˜¯çœŸå“ï¼Œéƒ½æ˜¯counterfeiteï¼Œè‡ªè¡Œè¼¸å…¥æœƒåƒç‰¢é£¯ï¼Œæ‰€ä»¥é‡‘é–€å¤§æ¦‚åœ¨æ”¿æ²»å®£å‚³å§)
[è¨»: æ„Ÿè¬æˆ‘çš„å¸¥åŒå­¸æ±ŸOéºŸé†«å¸«æŒ‡æ­£: ä¸æ˜¯ç‰½ğŸ’ï¼Œæ›´ä¸æ˜¯ç‰½ğŸ·å“¥ï¼Œæ˜¯ã€Œç‰½æºä»”ã€ï¼Œè¡¨ç¤ºç‰½ç·šçš„æ„æ€]
è¼ç‘å’ŒBioNTechæ˜¯åˆä½œå¤¥ä¼´ï¼Œ BioNTechå’Œå¤æ˜Ÿæ˜¯åˆç´„åˆä½œï¼Œä½†æ˜¯ã€ä½†æ˜¯ï¼Œä¸ä»£è¡¨è¼ç‘å’Œå¤æ˜Ÿæ˜¯åˆä½œé—œä¿‚ï¼Œè¼ç‘æ²’æœ‰å®£ç¤ºä»»ä½•å’Œå¤æ˜Ÿåˆä½œçš„é—œä¿‚ (æ²’æœ‰ä¸‰æ–¹åˆç´„)ã€‚æ‰€ä»¥ä¸­åœ‹å¤æ˜Ÿè¦å‘ä¸­åœ‹è—¥ç›£å–®ä½ç”³è«‹BLAæ™‚ï¼Œæ“šèªªåªèƒ½å‘è¼ç‘èŠ±å¤§éŒ¢è³¼è²·submission data (ç ”ç™¼è²»ç”¨æ˜¯Pfizer / BNTä¸€äººä¸€åŠï¼Œè¼ç‘å…ˆä»£å¢Šï¼Œä¹‹å¾ŒBNTç”±Pfizer loyalty ä¸­åˆ†æœŸæ‰£é‚„)ï¼Œä½†æ˜¯ç›®å‰ä¸­åœ‹åœ‹å®¶è—¥å“ç›£ç£ç®¡ç†å±€NMPAæ²’æœ‰è·¡è±¡åœ¨çŸ­æ™‚é–“å…§approve (or EUA)ï¼Œè€Œä¸”BNT162b2çš„BLA submission æ˜¯ä»¥å¤–å•†å…¬å¸å¼•ç”¨global data ç”³è«‹ï¼Œä¸æ˜¯ä¸­åœ‹æœ¬åœŸè‡ªä¸»ç ”ç™¼ã€‚(é›–ç„¶è™Ÿç¨±BNT162b1çš„Phase1å’ŒPhase 2ä¸å®Œæ•´è³‡æ–™ä¹Ÿè¦å‘ˆå ±å‚™æŸ¥)ã€‚
è‡³æ–¼BNT162b1å’ŒBNT162b2æœ‰ä½•ä¸åŒï¼Ÿ 
- BNT162b1: æŠ—åŸåªä¾·é™åœ¨Spike glycoprotein (æ£˜è›‹ç™½)çš„receptor binding domain (RBD)ï¼Œé€™æ˜¯å’Œäººé«”angiotensin converting enzyme -2 receptor (ACE-2) çµåˆé€²è€Œæ„ŸæŸ“ç´°èƒ(å¦‚pneumocyte)ã€‚
- BNT162b2: æŠ—åŸæ˜¯æ•´å€‹full-length spike glycoprotein (å…¨é•·æ£˜è›‹ç™½)ï¼Œä¿æœ‰è¼ƒå¤šantigenicity, immunogenicity diversities 

å…¶å¯¦å¤æ˜Ÿå¾å¾·åœ‹é€²å£çš„BNT162b2ï¼Œå¯ä»¥å¾ªæ­£å¸¸ç®¡é“å‘å°ç£TFDAç”³è«‹BNT162b2åœ¨å°EUAï¼Œå¤æ˜Ÿå·²ç¶“èŠ±éŒ¢è²·äº†è¼ç‘half-ownership çš„data ï¼Œç‚ºæŸ¥é©—ç™»è¨˜ç”¨çš„ï¼Œä¸éä¸€æ—¦é€äº†ï¼Œå¤æ˜Ÿå’Œä¸­åœ‹è™•å¿ƒç©æ…®åƒå°ç£è±†è…çš„æ”¿æ²»æ“å¼„ï¼Œä¸€å€‹ä¸­åœ‹çš„æ³¡æ³¡å°±æœƒè¢«å¹ç ´â‹¯â‹¯å› ç‚ºå°ç£ã€Œå¦ä¸€å€‹åœ‹å®¶ã€å’Œæ¸¯æ¾³ã€Œåœ°å€ã€ä¸åŒï¼Œæ‰€ä»¥biologic license submissions (BLA)   é€æ¡ˆçš„ç¨‹ç´šä¸ä¸€æ¨£ï¼Œå¤æ˜Ÿå¹¾ä¹å¯ä»¥åœ¨æ¸¯æ¾³ï¼Œç¶“éè¼ƒç°¡å–®çš„æµç¨‹ï¼Œå¾ˆå¿«ç›´æ¥é€ä¸Šå¸‚ã€‚ä½†åœ¨å°ç£å¿…é ˆæœ‰å„ç¨®ç–«è‹—(ç”Ÿç‰©è£½åŠ‘)é€²å£å¯©æŸ¥è¦ç¯„ã€‚åŸºæœ¬ä¸Šï¼šå¤æ˜ŸBLAé€æ¡ˆç­‰åŒã€Œå¤–å•†ã€ã€‚ ä¹Ÿå°±æ˜¯èªªï¼šä¸­åœ‹å¤æ˜Ÿ=å¤–å•† â‹¯â‹¯é¢å°å°ç£æ˜¯ä¸€å€‹åœ‹å®¶ï¼Œç¨ç«‹è‡ªä¸»å¯©æŸ¥ï¼Œé‚£å¤æ˜Ÿå’Œä¸­åœ‹è¾›è¾›è‹¦è‹¦ç¶“ç‡Ÿåƒå°ç£è±†è…(ä¸€ä¸­æ³¡æ³¡)çš„ç›®çš„å°±è¢«å¹ç ´äº†ï¼
ä¸çŸ¥é“å¤æ˜ŸèƒŒå¾Œçš„å¤§äººæ…‹åº¦å¦‚ä½•ï¼Ÿä¸éå¦‚æœå°ç£è¦è²·ï¼Œå¤æ˜Ÿå°±å¾—é€ã€‚ä½†æ˜¯é€äº†ï¼Œã€Œä¸€å€‹ä¸­åœ‹ã€æ³¡æ³¡å°±ç ´äº†ï¼Œæ‰€ä»¥å¤æ˜Ÿä¸çŸ¥é“æ•¢ä¸æ•¢é€? ï¼ˆæ‹‰æ¿å‡³ï¼Œç´…èŒ¶çå¥¶ğŸ§‹â‹¯â‹¯)
BLA submission to NMPAå¿…é ˆä½¿ç”¨ä¸­æ–‡åå­—ï¼Œå°±æ˜¯ã€Œå¤å¿…æ³°ã€ï¼Œä½†æ˜¯åƒ…é™æ–¼ä¸­åœ‹ï¼Œæ¸¯æ¾³ï¼ æ‰€ä»¥ã€Œå¤å¿…æ³°ã€åœ¨è¼ç‘çš„archive å’Œç³»çµ±ä¸­ä¸¦æ²’æœ‰è¢«å¼•å…¥æˆ–æ¡ç”¨ï¼Œæ‰€ä»¥ã€Œå¤å¿…æ³°ã€æ˜¯å¤æ˜Ÿå’ŒBNTæˆæ¬Šå…±ç”¨çš„ä¸­æ–‡å•†å“å(å¾·åœ‹é€²å£)ï¼Œä½†æ˜¯ä¸æ˜¯è¼ç‘çš„ä¸­æ–‡å•†å“åï¼Œæˆ–è€…æ˜¯èª¬ä»¥è¼ç‘çš„è§’åº¦æ²’æœ‰ä¸­æ–‡å(è¯èªåœ‹å®¶éƒ½è¢«å¤æ˜Ÿå«æ‹¬äº†)ï¼Œå› ç‚ºè¼ç‘å’Œå¤èˆˆæ²’æœ‰åˆä½œé—œä¿‚ã€‚é€™å’Œä»¥å‰ä¸­åœ‹è¼ç‘æœ‰ä¸­åœ‹ä¸­æ–‡å•†å“åï¼Œé¦™æ¸¯è¼ç‘æœ‰é¦™æ¸¯ç¹é«”ä¸­æ–‡åï¼Œå°ç£è¼ç‘æœ‰å°ç£ç¹é«”ä¸­æ–‡åä¸ä¸€æ¨£ã€‚ (è¨»ï¼šä¸­åœ‹è¼ç‘ã€å°ç£è¼ç‘æ²’æœ‰ç¶“æ‰‹BNT162b2ï¼ŒğŸ˜­)

## æ–°èæ•´ç†
### 2021/5/26 14:00 ä¸­å¤®æµè¡Œç–«æƒ…æŒ‡æ®ä¸­å¿ƒåš´é‡ç‰¹æ®Šå‚³æŸ“æ€§è‚ºç‚è¨˜è€…æœƒ
45:34
51:20

### Fosun Press Releases
https://www.fosunpharma.com/en/news/groupNews.html

### BioNTech Press Releases
https://investors.biontech.de/press-releases

## è¨è«–
### é‘‘åˆ¥æ˜¯å¦å¯ä»¥åˆ†è¾¨BNT162b1å’ŒBNT162b2?

>1. ã€Œé‘‘åˆ¥ã€ä¸çŸ¥é“æœ‰æ²’æœ‰åŒ…å«"identity test"?[^second]
>...åœ¨ç¾åœ°å°å­˜ç–«è‹—å¾Œå°‡æ¨£å“æ”œå›é£Ÿè—¥ç½²åœ‹å®¶å¯¦é©—å®¤é€²è¡Œå¤–è§€ã€==é‘‘åˆ¥==ã€pHå€¼ã€DNA/proteinæ¯”ä¾‹ã€ç´°èŒå…§æ¯’ç´ ã€ç„¡èŒåŠç•°å¸¸æ¯’æ€§ç­‰7é …è©¦é©—ï¼Œç¶“é£Ÿè—¥ç½²åŒæ­¥å¯©æŸ¥æ–‡ä»¶è³‡æ–™èˆ‡æª¢é©—çš†åˆæ ¼å¾Œ...è©²æ‰¹ç–«è‹—å³å¯äº¤ç”±ç–¾ç—…ç®¡åˆ¶ç½²é€²è¡Œå¾ŒçºŒç–«è‹—æ¥ç¨®ä½œæ¥­ã€‚[^first].
>2. ç¾è¡Œidentity testæ˜¯å¦å¯å€åˆ¥BNT162b1å’ŒBNT162b2?
>[name=planty]


[^first]:  [é£Ÿå“è—¥ç‰©ç®¡ç†ç½²å®Œæˆé˜¿æ–¯ç‰¹æ·åˆ©åº·(AstraZeneca)å…¬å¸è¼¸å…¥é¦–æ‰¹COVID-19ç–«è‹—æª¢é©—ä¸¦æ ¸ç™¼å°ç·˜è­‰æ˜æ›¸](https://www.mohw.gov.tw/cp-16-58703-1.html)         (2021/03/17)

[^second]: [Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum](https://www.fda.gov/media/144416/download)
    > The analytical procedures developed and used for the release and stability monitoring of
BNT162b2 DS and DP include tests to ensure their identity, purity, quality, and potency.